Terms: = Bone cancer AND RPL22, EAP, 6146 AND Treatment
17 results:
1. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
[TBL] [Abstract] [Full Text] [Related]
2. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
[TBL] [Abstract] [Full Text] [Related]
3. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
Bracarda S; Galli L; Maruzzo M; Lo Re G; Buti S; Favaretto A; Di Costanzo F; Sacco C; Merlano M; Mucciarini C; Zafarana E; Romito S; Maestri A; Giorgio CG; Ionta MT; Turci D; De Giorgi U; Procopio G; Cortesi E; Giannarelli D; Porta C
Future Oncol; 2018 Jun; 14(14):1347-1354. PubMed ID: 29774766
[TBL] [Abstract] [Full Text] [Related]
4. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O; Vogelzang NJ; Sweeney C; Fernandez DC; Almeida F; Iagaru A; Brown A; Smith MR; Agrawal M; Dicker AP; Garcia JA; Lutzky J; Wong YN; Petrenciuc O; Gratt J; Shore ND; Morris MJ;
Oncologist; 2018 Feb; 23(2):193-202. PubMed ID: 29183960
[TBL] [Abstract] [Full Text] [Related]
5. [Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (eap)].
Huang H; Zhang Y; Zhao HY; Wang ZQ; Xu F; Xu GC; Zhang L; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):148-51. PubMed ID: 19538895
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of breast cancer cell adhesion and bone metastasis by the extracellular adherence protein of Staphylococcus aureus.
Schneider D; Liaw L; Daniel C; Athanasopoulos AN; Herrmann M; Preissner KT; Nawroth PP; Chavakis T
Biochem Biophys Res Commun; 2007 May; 357(1):282-8. PubMed ID: 17418809
[TBL] [Abstract] [Full Text] [Related]
7. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract] [Full Text] [Related]
8. A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease.
Reichle A; Bolder U; Bataille F; Messmann H; Wagner H; Zaiss M; Wild P; Hofstädter F; Andreesen R; Jauch KW
Bone Marrow Transplant; 2003 Oct; 32(7):665-71. PubMed ID: 13130313
[TBL] [Abstract] [Full Text] [Related]
9. A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia.
Cherry AM; Bangs CD; Jones P; Hall S; Natkunam Y
Cancer Genet Cytogenet; 2001 Sep; 129(2):155-60. PubMed ID: 11566347
[TBL] [Abstract] [Full Text] [Related]
10. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Hartmann JT; Quietzsch D; Daikeler T; Kollmannsberger C; Mayer F; Kanz L; Bokemeyer C
Anticancer Drugs; 1999 Sep; 10(8):729-33. PubMed ID: 10573205
[TBL] [Abstract] [Full Text] [Related]
11. treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
Naito S; Ueda T; Kotoh S; Kumazawa J; Itoh K; Sagiyama K; Omoto T; Andoh S; Hasegawa Y; Fujisawa Y
Cancer Chemother Pharmacol; 1995; 35(3):225-9. PubMed ID: 7805181
[TBL] [Abstract] [Full Text] [Related]
12. [Four cases of advanced adenocarcinoma showing marked response to eap (etoposide, ADM, CDDP) treatment].
Iba T; Yagi Y; Kidokoro A; Fukunaga M; Fukunaga T; Mishima S
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2383-5. PubMed ID: 8259856
[TBL] [Abstract] [Full Text] [Related]
13. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of advanced gastric cancer.
Suzuki T; Ochiai T; Nagata M; Koide Y; Gunji Y; Nakajima K; Yokoyama T; Kashiwabara H; Isono K
Cancer; 1993 Nov; 72(9):2537-42. PubMed ID: 8402473
[TBL] [Abstract] [Full Text] [Related]
14. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
[TBL] [Abstract] [Full Text] [Related]
15. [A case of gallbladder cancer with marked response to eap treatment].
Iba T; Fukunaga T; Sugiyama K; Kawabata M; Fukunaga M; Kidokoro A; Yagi Y
Gan To Kagaku Ryoho; 1992 Jun; 19(6):897-900. PubMed ID: 1605668
[TBL] [Abstract] [Full Text] [Related]
16. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.
Lerner A; Gonin R; Steele GD; Mayer RJ
J Clin Oncol; 1992 Apr; 10(4):536-40. PubMed ID: 1548518
[TBL] [Abstract] [Full Text] [Related]
17. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
Kelsen D; Atiq OT; Saltz L; Niedzwiecki D; Ginn D; Chapman D; Heelan R; Lightdale C; Vinciguerra V; Brennan M
J Clin Oncol; 1992 Apr; 10(4):541-8. PubMed ID: 1548519
[TBL] [Abstract] [Full Text] [Related]
